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a b s t r a c t
An experimental contraceptive vaccine was evaluated in Atlantic salmon (Salmo salar). A peptide derived
from the beta subunit of luteinizing hormone (LH) was conjugated to two different carrier proteins,
bovine serum albumin (BSA) and keyhole limpet hemocyanin (KLH), and formulated with one of four
immunostimulants in a water-in-oil emulsion. Specific antibody responses to the peptide and each
carrier protein were evaluated. While the antibody response to KLH was stronger than the response to
BSA, both carrier proteins stimulated comparable antibody responses to the LH peptide. The immu-
nostimulant proved to be more important for enhancing the LH peptide antibody response than the
carrier protein selection; vaccines containing a combination of Aeromonas salmonicida and Vibrio
anguillarum stimulated significantly greater LH peptide antibody production than any of the other three
immunostimulants evaluated at 12 weeks post-vaccination. This study provides proof-of-concept for
specific antibody production against a hapten-carrier protein antigen in Atlantic salmon and reinforces
the importance of vaccine immunostimulant selection.
© 2017 Published by Elsevier Ltd.
1. Introduction/background
Aquaculture is the fastest growing food-animal producing sector
[1] and provides 47% of fish for human consumption [2]. The United
Nations Food and Agriculture Association (FAO) predicts that the
global demand for seafood will increase 25% through 2030. As wild
fish stocks have diminished and food security continues to be a
global issue, sustainable fish farming practices are of increasing
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importance and are being heavily scrutinized by governmental and
environmental agencies.
More than 14% of fish produced globally are salmonids [2]. With
aquaculture production of salmonids expanding at an average
annual rate of nearly 10% [2], there is an increasing risk of farmed
salmon inadvertently escaping into bodies of water inhabited by
wild fish populations [3e6]. Farmed salmon all originate from a
limited set of lineages and have substantially reduced genetic di-
versity due to founder effects, and other selection-related factors
[7]. Asynchrony in release of sperm and eggs, a lack of dominance
relationships among males, indiscriminate aggression, and various
other behavioral dynamics lead to reduced reproductive success in
farmed Atlantic salmon [8,9]. Despite the reduced breeding per-
formance of escaped farmed salmon, they are still able to breed
with wild salmon, thereby altering the genetics of those unique
wild populations and negatively affecting population survival
[7,9e12]. Even sterile, induced-triploid male Atlantic salmon have
been observed to exhibit spawning behaviors and induce wild fe-
males to spawn in the absence of a wild male [13], potentially
affecting seasonal reproductive success.
Immunocontraception could provide a means to prevent
escaped salmon from cross-breeding with wild salmon. If admin-
istered at the proper stage in a fish's development, a contraceptive
vaccine could also potentially prevent fish from sexually maturing
[14].
Gonadotropin releasing hormone (GnRH) is an important
regulator of sexual maturation and reproduction. Two forms of
GnRH are synthesized in the hypothalamus and transported via
neurons to the pituitary [15e18]. In the pituitary, GnRH stimulates
secretion of two protein hormones, gonadotropin I (GTH-I) and
gonadotropin II (GTH-II), also known as follicle stimulating hor-
mone (FSH) and lutenizing hormone (LH) respectively, which are
carried to gonads in the bloodstream [15,19]. The primary role of
FSH in fish is to stimulate gonad development, while both FSH and
LH regulate functions of the mature reproductive system, such as
ovulation and sperm release [20,21]. FSH and LH both consist of an
alpha subunit, necessary for structural integrity, and a beta subunit,
which is the biologically active portion of the molecule [14].
Vaccination against selected infectious diseases in large-scale
aquaculture operations is standard practice, especially for high-
value species like Atlantic salmon [22]. Both adaptive and innate
immune responses are observed in teleosts [23], though the innate
system is thought to be more highly developed [24]. Most aqua-
culture vaccine antigens are poorly immunogenic on their own and
requiremodification or formulationwith an adjuvant to sufficiently
excite the immune system [22,25].
Thus, as both endogenous and very small molecules, most
reproductive peptides in a vaccine would fail to elicit any sort of
immune response. Large foreign molecules such as keyhole limpet
hemocyanin (KLH) and bovine serum albumin (BSA) are easily
identified as non-self and are useful for increasing immunogenicity
of small or minimally immunogenic antigens [26]. KLH and BSA are
readily taken up by antigen presenting cells (APCs) in teleosts
[26e28] and aid in antigen uptake by recruiting T-helper cells [29]
which make them well suited as carrier proteins.
Oil-based adjuvants may prolong the duration of antigen pre-
sentation due to a depot effect [22] wherein clearance of the an-
tigen from the injection site is slowed [29]. Antigen uptake is also
facilitated by oil-adjuvanted vaccines through varying degrees of
tissue damage at the vaccine injection site [30]. Water-in-oil
emulsions are the most common form of oil-adjuvanted vaccines.
Other adjuvants, referred to as immunostimulants, stimulate
non-specific immune responses and often amplify specific immune
responses, thereby improving potency and efficacy [26,31]. This is
usually accomplished via enhanced antigen presentation or
stability [32], immunomodulation [29], or by eliciting easily
recognized ‘danger’ signals that stimulate immune system activa-
tion [30].
Toll-like receptors and pattern recognition receptors bind a
wide range of molecules exhibiting conserved pathogen-associated
molecular patterns (PAMPs) [30], such asmuramyl dipeptide (MDP)
[33,34] and beta-glucans derived from yeast and fungi. These
compounds are proven immunostimulants and immunomodula-
tors in fish vaccines [29,34]. Bacteria are often an antigen in
aquaculture vaccines and are not conventionally classified as
immunostimulants. However, bacteria can act as an adjuvant when
mixed with protein antigens by inducing macrophages to stimulate
differentiation and proliferation of T cells specific to the protein
antigen [35]. In this manuscript, we will refer to bacteria included
in vaccine as an ‘immunostimulant’ due to its intended purpose as
adjuvant rather than antigen.
This manuscript reports the findings from a study that was
conducted to evaluate antibody production in Atlantic salmon
injected with experimental vaccine formulations containing a LH
peptide conjugated to a carrier protein. The purposes of this study
were to: 1) assess the feasibility of stimulating antibody production
against an endogenous reproductive peptide, 2) compare immu-
nogenicity of two different carrier proteins, 3) determine which of
four immunostimulants is most efficient at exciting non-specific
antibody production, and 4) evaluate the suitability of a partic-
ular oil adjuvant for use in Atlantic salmon.
2. Materials and methods
2.1. Fish
Atlantic salmon (n ¼ 503; Bolaks breed), hatched at the Nofima
Marin Sunndalsøra Research Station (Sunndalsøra, Norway), were
used in this study. Upon study initiation, mean fish weight was
approximately 174 g (±1.2 g), smoltification was underway but
incomplete, and none of the fish had received any other vaccina-
tions. After three weeks in quarantine, acclimation to the housing
conditions and smoltification were complete. The salmon were
anesthetized in a 50 mg/L solution of Finquel®/MS-222 (tricaine
methanesulfonate) (Scan Aqua AS; Hvam, Norway), and a passive
integrated transponder (PIT tag) was inserted in the ventral area of
the abdominal cavity (fatty tissue posterior to the pyloric ceca) for
unique identification.
2.2. Rearing conditions
Vaccine trials were conducted at Nofima Marin facilities in
Sunndalsøra, Norway in eight 250-L indoor tanks. The salmonwere
sustained on a diet of Nutra Olympic feed (3 mm; Skretting; Sta-
vanger, Norway) provided by an automatic feeding system. Using a
random number generator, each salmon was randomly assigned to
one of nine treatment groups (55e56 fish per treatment group) and
randomly assigned to one of eight tanks (62e63 fish per tank).
Water temperature was maintained between 8 and 9 C for the
duration of the study.
2.3. Vaccines
There is wide agreement in the literature that intraperitoneal
vaccination with 100e200 mL of oil-adjuvanted vaccine is appro-
priate for immunocompetent salmonids [27,36,37].
2.3.1. Vaccine compositions
Eight different contraceptive vaccine formulations (treatments
1e8) and a control vaccine (treatment 0) were manufactured in a
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cleanroom at the National Wildlife Research Center (Fort Collins,
Colorado, USA). All vaccines (except the control) contained
0.222 mg/mL of an 18 amino acid peptide derived from the beta
subunit of the salmon LH protein (referred to as LH-b peptide
herein) (GL Biochem (Shanghai) Ltd.; Shanghai, China). The peptide
was conjugated to a carrier protein, either BSA or KLH (Thermo
Fisher Scientific; Waltham, Massachusetts), per the carrier protein
manufacturer recommendations. Briefly, for each vaccine formu-
lation, 10 mg of maleimide-activated BSA or KLH was incubated
with 8 mg of LH-b peptide in 3 mL of 0.03 M phosphate buffered
saline (PBS) at 24 C for 2 h. The conjugate was incorporated in the
vaccines at a final concentration of 0.50 mg/mL [27,38,39]. Each
vaccine also contained one of four immunostimulants at a con-
centration of 0.50 mg/mL or 8.3  104 cells/mL, including muramyl
dipeptide, beta glucans, killed Aeromonas salmonicida and Vibrio
anguillarum mixture, and killed Mycobacterium marinum.
2.3.2. Immunostimulant preparation
Ac-muramyl-Ala-D-Glu-NH2 muramyl dipeptide (MDP) was
sourced from Bachem Americas, Inc. (Torrance, California) and used
without modification.
MacroGard® purified beta-1,3/1,6-glucans (Biorigin Europe;
Antwerp, Belgium) was treated for 20 min at 80 C to inactivate
bacterial and fungal constituents. Once cooled, it was resuspended
at 9 mg/mL in sterile 0.01 M PBS on ice and sonicated for 30 s twice
to minimize clumping.
Mycobacterium marinum ATCC® 927™ was cultured on Mid-
dlebrook and Cohn 7H10 agar slants (BD Diagnostic Systems;
Sparks, Maryland) at 30 C for 9 days. A single colony ofM.marinum
was then inoculated into 50 mL of pre-warmed Middlebrook 7H9
broth with glycerol and ADC enrichment in a sterile 250 mL culture
flask and incubated with continuous shaking for 23 days in the
dark. Once confluent and in the late log-phase of growth (3 pas-
sages), the cells were heated at 121 C for 30 min. Approximately
45 mL of the killed cell suspension was centrifuged for 10 min at
2500g. The supernatant was aspirated and the pelleted cells were
resuspended in 30 mL of sterile 0.01 PBS. The cells were washed
twice more and resuspended in 10 mL sterile 0.01 M PBS. The cell
suspension was passed through a 26 gauge needle three times and
then centrifuged at 100g for 2 min to recover a single-cell pop-
ulation. The concentration of the single-cell suspension was
determined using a Sceptre handheld automated cell counter (EMD
Millipore; Billerica, Massachusetts).
Advantigen® vaccine (Microtek International Inc.; Saanichton,
British Columbia) was used as the source of A. salmonicida and
V. anguillarum serotypes 01 and 02. The Advantigen was aliquoted
in 15 mL conical tubes and centrifuged at 4 C for 20 min at
approximately 3700g. The pelleted cells were transferred to clean
tubes, resuspended in sterile 0.01 M PBS, and centrifuged for
another 10 min. Cell concentration was again determined using a
Sceptre handheld automated cell counter (EMD Millipore).
2.3.3. Vaccine preparation
The vaccine aqueous phases, containing carrier-peptide conju-
gate and immunostimulant in sterile 0.01 M PBS, were combined
with Seppic Montanide™ ISA 761 VG (Air Liquide; Puteaux, France)
adjuvant (30:70 v/v) using a stand mixer with an impeller style
blade to form a water-in-oil emulsion. The primary emulsion was
passed one time through a Microfluidizer® Processor (Microfluidics
Corporation; Westwood, Massachusetts). Sterile, rubber latex-free,
single-use syringes were filledwith individual doses of 0.2mL. Each
vaccine formulation contained the same peptide, one of two carrier
proteins, and one of four immunostimulants, as designated in
Table 1 as final concentrations.
2.4. Sampling and vaccination
Four weeks after PIT tagging, salmon were anesthetized as
described above, and a 21 gauge needle was used to draw
0.5e1.0mL of blood from the caudal vein. Following the blood draw,
0.2 mL of contraceptive vaccine was injected into the peritoneal
cavity of each fish. Additional blood samples were taken at 8 and 12
weeks post-vaccination. All blood samples were collected in
microcentrifuge tubes, allowed to clot at room temperature, and
then centrifuged at 1000e2000g for 10 min. Sera were trans-
ferred to clean microcentrifuge tubes and stored at 80 C until
analyzed. The weight and length of each fish were also measured at
each sampling time point. Upon study termination, the fish were
euthanized with an overdose of Finquel®.
2.5. Antibody responses
Three enzyme-linked immunosorbent assays (ELISAs) were
developed to semi-quantitatively measure the presence of anti-
bodies specific to the vaccine components; namely the LH-b pep-
tide, BSA, and KLH.
Due to the small molecular size of the LH-b peptide, a conjugate
was prepared for use as antigen. The LH-b peptide was conjugated
to ovalbumin (OVA) (Thermo Fisher Scientific) using SM(PEG)2
crosslinker (Thermo Fisher Scientific). Briefly, 4.5 mg of ovalbumin
was reacted with 1 mmole of crosslinker for 30 min at 24 C in 1 mL
of molecular-grade water. Excess crosslinker was removed using a
Sephadex G25 column (GE Healthcare; Little Chalfont, United
Kingdom). The activated ovalbuminwas then mixed with 8.3 mg of
LH-b peptide in a total volume of 4.5 mL and incubated for 30 min
at 24 C. The resulting conjugate was loaded onto two PD10
Sephadex G25 columns, each eluted with 3.5 mL of 0.1 M PBS. The
final protein concentration of the conjugate was determined by
Bradford assay.
2.5.1. ELISA protocol
Salmon sera were diluted 1:10 in ‘milk block’ (5% w/v powdered
skimmilk in 0.01 M PBS with 5% Tween 20 (Amresco; Framingham,
Massachusetts)) and stored at 4 C overnight for pre-adsorbtion of
serum antibodies [37]. 96-well high-bind polystyrene plates (Santa
Cruz Biotech; Santa Cruz, California) were coated with 50 mL of
antigen in either 0.05 M carbonate-bicarbonate buffer (Sigma-
Aldrich; St. Louis, Missouri) or 0.01 M PBS (Sigma-Aldrich). Plates
were stored overnight at 4 C thenwashed three times with 200 mL
of 0.01 M PBS with 0.05% Tween 20 (PBST) (Sigma-Aldrich). Each
well was incubated with 200 mL of milk block for 1 h at 24 C. Plates
were washed three times with 200 mL PBST. Duplicate wells were
loaded with 50 mL pre-adsorbed sera and plates were incubated for
1 h at 24 C before being washed three times with 200 mL PBST.
Monoclonal mouse anti-salmonid Ig antibody conjugated to
horseradish peroxidase (HRP) (US Biological; Salem, MA) was
diluted 1:1000 in 0.01 M PBS and 50 mL was added to each well.
Plates were covered and incubated for 1 h at 24 C, then washed
three times with 200 mL wash buffer. Enzyme substrate was pre-
pared by dissolving 1 mg of 3,30,5,50-tetramethylbenzidine dihy-
drochloride (Sigma-Aldrich) per 10 mL of 0.05 M phosphate citrate
buffer with 0.014% hydrogen peroxide (Sigma-Aldrich). 50 mL of
enzyme substrate was added to each well and plates were incu-
bated at 24 C for a fixed time before the reactionwas stopped with
50 mL of 2 M sulfuric acid and optical density was measured at a
single wavelength of 450 nm. Table 2 provides additional detail
about the variations on this generic protocol that are specific to
each antigen evaluated. All plates were run with positive control
and negative control samples, identified during assay development.
D.S.O. Mora et al. / Fish & Shellfish Immunology 71 (2017) 255e263 257
2.6. Statistical analyses
There were 503 fish on trial initially but some of the fish were
lost due to complications with the blood draws at each sampling
time. As such, the number of samples from each treatment group
and each time point decreased as the study progressed for a final
count of 418 fish upon study termination, as shown in Table 3.
Antibody production was evaluated using optical densities
(ODs) measured by the ELISAs. Samples were included in the
dataset if the duplicate well ODs had a coefficient of variation (CV)
less than 15%; if the CV exceeded 15% and one or both duplicate
sample ODs were greater than the assay limit of detection, the
sample was re-run.
Assay background was accounted for by subtracting the mean
OD of wells incubated with PBS instead of serum, included on every
plate. To account for inter-plate variation, results are presented as
sample to positive ratios minus the mean pre-vaccination OD for
that treatment [40e42].
A Kruskal-Wallis one-way analysis of variance (ANOVA) was
used to compare the median pre- and post-vaccination ODs among
all treatment groups [43]. In the event of a significant difference,
pairwise comparisons of medians were made using Dunn's multi-
ple comparisons test (among treatments at a given time, andwithin
a single treatment over time). The datawere not treated as repeated
measures because treatment was applied between the first and
second sampling times and sample sizes were unequal among
treatments and within treatments over time.
Positive/negative thresholds for each ELISA were set to maxi-
mize sensitivity and specificity. Receiver operator characteristic
(ROC) graphs were generated [43] for each ELISA using threshold
values ranging from the minimum to maximum OD value for the
assay in increments of 0.001. The OD corresponding to the optimum
sensitivity and specificity was set as the positive/negative threshold
for each assay.
Mean fish weights and lengths were compared among treat-
ment groups using one-way ANOVA.
Minitab (version 16, Minitab, Inc.; State College, Pennsylvania)
and GraphPad Prism (version 6.07 GraphPad Software; La Jolla,
California) statistical packages for Windows were used for the
above statistical analyses.
3. Results
3.1. Assay positive/negative thresholds
The ROC curves generated for each assay are shown in Fig. 1.
Area under the curve (AUC) corresponds to the probability of a
Table 1
Comparison of Atlantic salmon contraceptive vaccine formulations.
Formulation # Peptide Peptide Conc. (mg/mL) Carrier Carrier Conc. (mg/mL) Immunostimulant Immunostimulant Conc. Adjuvant
0 (sham) none 0 none 0 none 0 ISA761 VG
1 LH-b 18mer 0.222 BSA 0.278 b-glucan 0.5 mg/mL ISA761 VG
2 LH-b 18mer 0.222 KLH 0.278 b-glucan 0.5 mg/mL ISA761 VG
3 LH-b 18mer 0.222 BSA 0.278 Muramyl dipeptide 0.5 mg/mL ISA761 VG
4 LH-b 18mer 0.222 KLH 0.278 Muramyl dipeptide 0.5 mg/mL ISA761 VG
5 LH-b 18mer 0.222 BSA 0.278 A. salmonicida þ V. anguillarum 8.3  104 cells/mL ISA761 VG
6 LH-b 18mer 0.222 KLH 0.278 A. salmonicida þ V. anguillarum 8.3  104 cells/mL ISA761 VG
7 LH-b 18mer 0.222 BSA 0.278 M. marinum 8.3  104 cells/mL ISA761 VG
8 LH-b 18mer 0.222 KLH 0.278 M. marinum 8.3  104 cells/mL ISA761 VG
Table 2
Antigen-specific modifications to the generic ELISA protocol provided for detection of antibodies to BSA, KLH, and LH in Atlantic salmon.
Antigen Antigen Conc. (ng/mL) Coating Buffer Substrate Dev. (minutes)
BSA 10 Carb-bicarb 15
KLH 5 Carb-bicarb 11
LH-b conjugate 3.74 PBS 11
Table 3
Number of salmon in each treatment group sampled at each time point in the study.
Treatment Group Pre-vaccination 8 wk Post-vacc. 12 wk Post-vacc.
0 56 51 48
1 56 49 46
2 55 51 49
3 56 51 46
4 56 51 43
5 56 43 42
6 56 47 43
7 56 51 49
8 56 50 48
TOTAL 503 452 418
Fig. 1. ROC curves; the solid line from (0,0) to (1,1) represents a 50% chance of positive
classification of a positive or negative sample.
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randomly selected vaccinate being classified as positive compared
to a randomly selected non-vaccinate receiving the same classifi-
cation using the same assay with a fixed threshold [44]. The AUC for
KLH was calculated to be 0.8930, suggesting that the assay does an
excellent job discriminating between positives and negatives. The
AUCs for the BSA and peptide assays were much lower at 0.5348
and 0.5648, respectively.
The optimum sensitivity and specificity for each assay and their
corresponding thresholds, set as the positive/negative thresholds,
are summarized in Table 4.
3.2. LH-b peptide antibody response
Overall, approximately 36% (303/849) of samples from fish
vaccinated against the peptide were identified as positive
(regardless of carrier; including 8 and 12 weeks post-vaccination).
This is further broken down by treatment in Fig. 2. For all treat-
ments, the proportion of samples positive for LH-b antibodies was
highest at 12 weeks post-vaccination.
3.3. Carrier proteins antibody response
Approximately 96% (361/376) of samples from fish vaccinated
against KLH and 76% (282/371) of samples from fish vaccinated
against BSA were identified as positive for antibodies to the
respective carrier protein. The proportion of positive samples was
highest at 12 weeks post-vaccination for both carrier proteins.
The proportion of samples classified as positive are shown
further broken down by treatment group to compare performance
of the formulations (Figs. 3 and 4). High background levels in the
anti-BSA and anti-peptide ELISAs are revealed by the large pro-
portion of samples in treatment 0 that are classified as positive,
despite the control group fish never having been vaccinated against
these antigens. A dashed line extends horizontally from the top of
the control group's bar to show themisclassification rate associated
with the assay at its positive/negative threshold.
3.4. Comparison of immunostimulants
Prior to vaccination, there was no significant difference in me-
dian BSA or KLH antibody levels among treatment groups
(p ¼ 0.707, 0.996 respectively).
No significant difference was detected in median BSA antibody
levels among treatment groups at 8 weeks post-vaccination
(p ¼ 0.171). However, a statistically significant difference in the
median BSA antibody response was detected at 12 weeks post-
vaccination (p < 0.0001); by this time, the median BSA antibody
level of treatment group 5 was significantly different from that of
all other groups except treatment 3 (p < 0.05) (Fig. 5, Table 5).
Interestingly, treatment 5 was the only one that produced a sig-
nificant difference between pre-vaccination and post-vaccination
BSA antibody levels and this was only seen at 12 weeks post-
vaccination (p < 0.001).
A statistically significant difference in the median KLH antibody
response was detected among treatment groups at 8 and 12 weeks
post-vaccination. All treatment groups vaccinated against KLH had
median responses that were significantly different than those of the
non-vaccinates (Fig. 6, Table 6). There was a significant difference
between median pre-vaccination and post-vaccination (both 8 and
12 weeks) KLH antibody levels in all four treatment groups vacci-
nated with KLH (p < 0.001). The 8 week and 12 week post-
vaccination median KLH antibody responses were significantly
different from each other in only two treatment groups, 2 and 6
(p < 0.05).
Prior to vaccination, there was a significant difference in median
LH-b antibody levels between treatment groups 1 and 5 (p < 0.01;
treatment 1 sum of ranks andmean of ranks greater than treatment
5). This leveled out by 8 weeks post-vaccination and no significant
difference was detected in the median LH-b antibody responses
among treatment groups at this time (p ¼ 0.210). However, a sta-
tistically significant difference in the median LH-b antibody
response was detected at 12 weeks post-vaccination (p < 0.0001)
Table 4
Summary of values for maximum sum of sensitivity and specificity, corresponding
positive/negative threshold, and individual sensitivity and specificity.
Antigen Max Sum Threshold (OD) Sensitivity Specificity
BSA 1.0894 0.0633974 0.2776 0.8118
KLH 1.6951 0.168481013 0.7686 0.9265
LH 1.1654 0.012 0.2603 0.9051
Fig. 2. Proportion of samples classified as positive for antibodies to LH-b peptide;
Treatments 1 through 8 contained the LH-b peptide. Treatment 0 was a sham vaccine
included as a control. 8 and 12 week post-vaccination samples are grouped together
and represented by a single bar for each treatment. A dashed line extends horizontally
from the top of the treatment 0 bar as an approximation of the misclassification rate
associated with the assay at its positive/negative threshold. (Treatment carrier protein/
immunostimulant content: 1: BSA/b-glucan, 2: KLH/b-glucan, 3: BSA/muramyl
dipeptide, 4: KLH/muramyl dipeptide, 5: BSA/A. salmonicida þ V. anguillarum, 6: KLH/
A. salmonicida þ V. anguillarum, 7: BSA/M. marinum, 8: KLH/M. marinum).
Fig. 3. Proportion of samples classified as positive for anti-BSA antibodies; Treat-
ments 1, 3, 5, and 7 contained BSA. 8 and 12 week post-vaccination samples are
grouped together and represented by a single bar for each treatment. The horizontal
dashed line shows the misclassification rate associated with the assay at its positive/
negative threshold. (Treatment carrier protein/immunostimulant content: 1: BSA/b-
glucan, 2: KLH/b-glucan, 3: BSA/muramyl dipeptide, 4: KLH/muramyl dipeptide, 5:
BSA/A. salmonicida þ V. anguillarum, 6: KLH/A. salmonicida þ V. anguillarum, 7: BSA/
M. marinum, 8: KLH/M. marinum).
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when treatment groups 5 and 6 were different from the control
group (p < 0.01) (Fig. 7, Table 7). Additionally, the median LH-b
antibody response of treatment group 5 was significantly different
from that of groups 2, 3, and 4 at 12 weeks post-vaccination.
Treatments 1 and 7 produced a significant jump in median LH-b
antibody production from 8 weeks to 12 weeks post-vaccination
(p < 0.001, p < 0.05 respectively) while treatment 8 had a signifi-
cant difference between pre-vaccination and 12 week post-
vaccination levels (p < 0.01). Treatments 5 and 6 produced a sig-
nificant difference in median LH-b antibody response between pre-
vaccination and 12 weeks post-vaccination (p < 0.001) and
between 8 and 12 weeks post-vaccination (p < 0.001).
3.5. Adjuvant suitability
Therewas not a significant difference inmean fish length among
treatment groups at any of the three time points (p ¼ 0.214, 0.178,
0.260 for pre-vaccination, 8 weeks, and 12 weeks post-vaccination,
respectively). Similarly, no significant difference in mean fish
weight was detected among treatment groups at any time
(p ¼ 0.158, 0.154, 0.080 for pre-vaccination, 8 weeks, and 12 weeks
post-vaccination, respectively).
4. Discussion
The findings of this study lay the foundation for further research
on development of contraceptive vaccines for Atlantic salmon and
indicate that a hapten-protein conjugate could be functional as a
vaccine antigen in this species. This study also reaffirms the value of
selecting an appropriate immunostimulant to enhance the immune
response to a vaccine antigen.
Antibody response to the LH-b peptide was low in both
magnitude and the proportion of positive samples. A simple option
for improving antibody response to the peptide may be to admin-
ister a boost dose of the vaccine. Drennan et al. [27] observed
minimal and inconsistent antibody responses in white sturgeon
(Acipenser transmontanus R.) vaccinated against a hapten-protein
antigen. However, after administering a boost dose of the vaccine,
a 16-fold titer increase was observed and the response rate jumped
to 100%. Similarly, rainbow trout (Onchorynkus mykiss) vaccinated
with a fluorescein isothiocyanate-KLH conjugate had low serum
antibody levels that were not differentiable from the control group
until after a booster vaccinewas administered [38]. In most species,
a boost dose administered at the appropriate time has been
observed to have this enhancing effect on antibody production and
Fig. 4. Proportion of samples classified as positive for anti-KLH antibodies;
Treatments 2, 4, 6, and 8 contained KLH. 8 and 12 week post-vaccination samples are
grouped together and represented by a single bar for each treatment. The horizontal
dashed line shows the misclassification rate associated with the assay at its positive/
negative threshold. (Treatment carrier protein/immunostimulant content: 1: BSA/b-
glucan, 2: KLH/b-glucan, 3: BSA/muramyl dipeptide, 4: KLH/muramyl dipeptide, 5:
BSA/A. salmonicida þ V. anguillarum, 6: KLH/A. salmonicida þ V. anguillarum, 7: BSA/
M. marinum, 8: KLH/M. marinum).
Fig. 5. Median BSA antibody production over time; treatments 1, 3, 5, and 7 contain
BSA; treatment group 5 shows a significant increase from 8 weeks to 12 weeks post-
vaccination. (Treatment immunostimulant content: 1: b-glucan, 3: muramyl dipeptide,
5: A. salmonicida þ V. anguillarum, 7: M. marinum).
Table 5
BSA antibody production over time (presented as median adjusted ODs).
Trt
Pre-vaccination 8 wk Post-vaccination 12 wk Post-vaccination
Median OD StDev n Median OD StDev n Median OD StDev n
0, 2, 4, 6, 8 0.010 0.049006 217 0.002 0.074969 194 0.009 0.131198 180
1 0.009 0.053386 56 0.009 0.055603 52 0.018 0.080978 48
3 0.004 0.024170 52 0.003 0.035719 48 0.003 0.066019 51
5 0.013 0.046256 55 0.001 0.071625 38 0.064 0.327983 42
7 0.015 0.081633 52 0.010 0.152953 44 0.020 0.200036 48
Fig. 6. Median KLH antibody production over time; treatments 2, 4, 6, and 8 contain
KLH; group 6 anti-KLH levels are the highest at 8 and 12 weeks post-vaccination, but
treatments 2, 4, and 8 also have elevated antibody levels compared to the groups
which were not vaccinated against KLH. (Treatment immunostimulant content: 2: b-
glucan, 4: muramyl dipeptide, 6: A. salmonicida þ V. anguillarum, 8: M. marinum).
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resulting protection [45]. Despite the known benefits of boosting, it
is desirable to achieve efficacy through a single vaccination due to
the cost of vaccines and manpower required to administer those
vaccines to fish [46]. Additionally, the stress of being handled and
vaccinated takes a toll on fish health so minimizing the number of
different vaccines necessary is advantageous [26]. Nevertheless, a
multiple vaccination scheme should not be ruled out until cost-
benefit analyses are conducted.
Treatments 5 and 6, which both contained A. salmonicida and
V. anguillarum as the immunostimulant, produced the strongest
antibody responses to both carrier proteins, and to the LH-b pep-
tide. Using multiple strains of whole bacteria as a vaccine immu-
nostimulant makes sense due to the number of different PAMPs
presented. In fish, PAMPs have been shown to elevate white blood
cell counts [30,47], stimulate non-specific immune mechanisms
[26,33], increase antigen uptake [34], enhance activation of
numerous immune components including granulocyte activity, and
increase resistance to infection from several bacterial pathogens
[30,33]. It is also possible that the enhanced antibody response
observed may be partially attributed to an overall increase in an-
tibodies, including those produced against the insoluble bacterial
immunostimulants. It is worth noting that all four of the immu-
nostimulants evaluated were insoluble bacteria or their derivatives,
all of which would theoretically elicit an antibody response. Future
studies should include groups of fish vaccinated with each indi-
vidual vaccine component to evaluate respective contributions to
the overall antibody response.
KLH was the strongest immunogen with the majority of fish
responding positively to this carrier protein. The larger molecular
size of KLH relative to BSA may have contributed to its superior
immunogenicity in Atlantic salmon. However, there was not a
statistically significant difference in the LH-b peptide response
between the BSA and KLH carrier groups; the enhanced KLH anti-
body responsewas not accompanied by a corresponding increase in
the LH-b response, indicating that both carrier proteins are suitable
for use in this particular application. This also suggests that, relative
to BSA, the stronger antibody response to KLH did not mask or
overwhelm the LH-b peptide antibody response. Within the pa-
rameters evaluated in the present study, it appears that the
immunostimulant choice has greater influence on the LH-b anti-
body response than does the choice of carrier protein.
Within treatment groups, there appears to be an association
between having a strong antibody response and having a large
proportion of responders. Interestingly, the proportion of re-
sponders to KLHwas significantly higher than that for BSA at both 8
and 12 weeks post-vaccination. The treatments with the largest
proportion of responders and strongest antibody responses for the
carrier proteins also had the highest proportion of responders to
the LH-b peptide. There was a great deal of variation in antibody
response among fish. Standard deviation was higher among vac-
cinates than among non-vaccinates.
The anti-BSA and anti-LH-b ELISAs provided predictive capa-
bility greater than random chance and allowed for rudimentary
statistical comparison of the various treatments. In maximizing the
sum of sensitivity and specificity, a large trade-off between the two
was observed, particularly for BSA and LH-b which had low AUCs.
This is not unexpected due to the nature of the relationship be-
tween sensitivity and specificity, but it does lead to low true
Table 6
KLH antibody production over time (presented as median adjusted ODs).
Trt Pre-vaccination 8 wk Post-vaccination 12 wk Post-vaccination
Median OD StDev n Median OD StDev n Median OD StDev n
0, 1, 3, 5, 7 0.012 0.0661714 274 0.011 0.073484 245 0.018 0.097673 238
2 0.007 0.0530410 55 0.185 0.443164 49 0.991 0.899854 50
4 0.002 0.0599784 55 0.155 0.456520 51 0.553 0.799839 43
6 0.019 0.0705586 56 0.675 0.736036 45 2.450 0.922341 43
8 0.013 0.0593099 56 0.145 0.324416 47 0.539 0.782617 48
Fig. 7. Median LH-b peptide antibody production over time; treatments 1 through 8
contain peptide; groups 5 and 6 have the highest median antibody levels 12 weeks
post-vaccination. (Treatment carrier protein/immunostimulant content: 1: BSA/b-
glucan, 2: KLH/b-glucan, 3: BSA/muramyl dipeptide, 4: KLH/muramyl dipeptide, 5:
BSA/A. salmonicida þ V. anguillarum, 6: KLH/A. salmonicida þ V. anguillarum, 7: BSA/
M. marinum, 8: KLH/M. marinum).
Table 7
LH-b peptide antibody production over time (presented as median adjusted ODs).
Trt Pre-vaccination 8 wk Post-vaccination 12 wk Post-vaccination
Median OD StDev n Median OD StDev n Median OD StDev n
0 0.002 0.009880 53 0.003 0.019656 48 0.002 0.020910 48
1 0.001 0.004308 56 0.002 0.011115 51 0.002 0.074569 49
2 0.001 0.010397 55 0.001 0.010483 50 0.001 0.034649 47
3 0.001 0.005855 53 0.001 0.014000 51 0.001 0.137381 46
4 0.000 0.005869 59 0.001 0.008323 51 0.000 0.019441 41
5 0.003 0.011769 59 0.001 0.074170 42 0.019 0.205364 36
6 0.002 0.009447 56 0.000 0.026871 53 0.010 0.230183 48
7 0.001 0.007395 55 0.001 0.042935 47 0.004 0.090234 49
8 0.001 0.007682 54 0.001 0.155469 46 0.003 0.206755 46
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positive rates for these assays while the true negative rates are very
high. Further optimization of these assays may be necessary in
future studies in order to provide improved differentiation between
true and false positives.
Since response rates were greatest at 12 weeks post-vaccination
and the study was terminated at that time, it is not possible to
ascertain whether peak antibody production was reached during
the span of the study. It will be necessary to conduct future trials in
a manner that allows for determination of time post-vaccination
when peak antibody production occurs for each antigen.
Fish weight and length were tracked to ensure that the vaccine
antigens did not adversely affect growth and to evaluate tolerability
to the Montanide ISA 761 VG adjuvant. None of the fish developed
gross lesions at the vaccine injection site and none of the fish
deaths that occurred during the study can be definitively attributed
to vaccination; most of the fish that died appeared to have suffered
nerve damage resulting from complications during blood sampling.
These observations do not provide any reason to suspect that the
adjuvant used in the study caused any adverse effects. The Mon-
tanide ISA 761 VG adjuvant appeared to be well tolerated by the
salmon but additional studies will be necessary to further evaluate
any potential side effects not externally visible and to assess growth
rate relative to an unvaccinated group.
The effects of vaccination on the reproductive physiology and
hormone production of the fish were not evaluated. Sambroni et al.
[14] vaccinated rainbow trout with phages displaying LH and FSH
receptors, resulting in specific antibody production, reduced hor-
mone levels, and delayed spermiation and vitellogenesis, suggest-
ing that disruption of this signaling pathway could prevent sexual
maturation of Atlantic salmon. Antibody responses are not always
predictive or correlative to the physiological effects of vaccination,
especially with immunocontraceptives, so a longer study duration
and evaluation of additional reproductive metrics is necessary. This
would be especially useful to determine whether any delay in
sexual maturation had positive outcomes related to improved body
condition and mass.
The findings of this study indicate that it is possible to stimulate
the immune system of Atlantic salmon to produce antibodies
against a small endogenous peptide conjugated to a carrier protein.
It was determined that KLH and BSA perform comparably as hapten
carriers and that an immunostimulant combining A. salmonicida
and V. anguillarum provides an improved antibody response. The
proportion of positive samples and antibody levels were highest at
12 weeks post-vaccination suggesting that the water-in-oil vaccine
provides a potentially extended release of antigen, possibly due to
granuloma formation as observed by Evensen et al. [48] or persis-
tent active inflammation [49]. Further research will be necessary to
improve the formulation of the contraceptive vaccine candidates
and determine the physiological significance of the resulting
antibodies.
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